SCHEMBL3303384

SCHEMBL3303384

CCOC(=O)Cc1c(C)c(Sc2ccc(-c3ncco3)cc2)n2cc(F)ccc12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGDR2 Q9Y5Y4 2/20 0.40
GAA P10253 2/20 0.38
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
ALDH1A1 P00352 3/20 0.33
TP53 P04637 2/20 0.33
USP2 O75604 1/20 0.33
MAPK14 Q16539 2/20 0.33
KDM4E B2RXH2 2/20 0.32
HPGD P15428 2/20 0.32
LMNA P02545 1/20 0.32
MAPT P10636 2/20 0.32
HSD17B10 Q99714 1/20 0.32
SLC34A1 Q06495 2/20 0.31
P2RX7 Q99572 1/20 0.31
SMN1; SMN2 Q16637 2/20 0.31
ADORA2A P29274 1/20 0.31
ADORA2B P29275 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3303558 0.89 PTGDR2 (0.50) PTGDR2P2RX7HCRTR1HCRTR2
SCHEMBL3306777 0.83 PTGDR2 (0.40) PTGDR2GAACYP1A2CYP3A4CYP2C9
SCHEMBL3303652 0.83 PTGDR2 (0.40) PTGDR2GAACYP1A2CYP3A4CYP2C9
SCHEMBL3302540 0.82 PTGDR2 (0.42) PTGDR2GAACYP1A2CYP3A4CYP2C9
SCHEMBL3304453 0.81 PTGDR2 (0.46) PTGDR2CYP1A2CYP3A4CYP2C9CYP2C19
SCHEMBL3302504 0.81 PTGDR2 (0.41) PTGDR2GAACYP1A2CYP3A4CYP2C9
SCHEMBL3569716 0.81 PTGDR2 (0.45) PTGDR2GAACYP1A2CYP3A4CYP2C9
SCHEMBL4440112 0.80 BRD4 (0.33) PTGDR2P2RX7HCRTR1HCRTR2
SCHEMBL3564465 0.79 PTGDR2 (0.52) PTGDR2GAACYP1A2CYP3A4CYP2C9
SCHEMBL3302617 0.78 PTGDR2 (0.40) PTGDR2CYP1A2CYP3A4CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100093751-A1 Indolizineacetic Acids and Their Therapeutic Use as Ligands of the CRTH2 Receptor ARGENTA DISCOVERY LIMITED (GB) 2010-04-15 US disclosed
EP-2121686-A1 INDOLIZINEACETIC ACIDS AND THEIR THERAPEUTIC USE AS LIGANDS OF THE CRTH2 RECEPTOR Argenta Discovery Limited (GB) 2009-11-25 EP disclosed
WO-2008078069-A1 INDOLIZINEACETIC ACIDS AND THEIR THERAPEUTIC USE AS LIGANDS OF THE CRTH2 RECEPTOR ARGENTA DISCOVERY LIMITED (GB) 2008-07-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100093751-A1 Indolizineacetic Acids and Their Therapeutic Use as Ligands of the CRTH2 Receptor HRH2, HRH4, HRH1 PTGDR2 168/4885GAA 4583/4885CYP1A2 1509/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.